Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pharma Roundup: Pfizer's Lipitor Patent, Wyeth and Crucell, and More
- Court re-validates Pfizer's Lipitor patent; Wyeth wants to buy Crucell; new spin-off Facet cuts jobs; Merckle family to sell Ratiopharm. by John Maas
- Blog posts 2009-01-07
Additional Resources
- Crucell Advances Hepatitis Vaccine in China
- ChinaBio Today submits: The Dutch biopharma Crucell N.V. CRXL said the SFDA released its hepatitis B vaccine Hepavax-Gene for registration and quality control in China. Crucell pointed out that Hepavax-Gene offers two advantages over competing products: its production is based on Crucell's hansenula polymorpha patented technology, a protein expression...
- External links 2008-12-10
- Crucell Notes Berna Announcement of Due Diligence Request
- Leiden, The Netherlands, December 19, 2005 - Crucell N.V. (Euronext, NASDAQ: CRXL) notes the announcement made by Berna Biotech AG yesterday of the request for due diligence information received from a third party, of which Berna had...
- Research articles 2005-12-19
- Crucell announces live webcast of Annual General Meeting of Shareholders
- Leiden, The Netherlands, May 30 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that there will be a live video webcast of the Annual General Meeting of Shareholders AGM, commencing June 1 at 14:00 hrs CET in Leiden. The webcast will be available...
- Research articles 2007-05-30
- Crucell Licenses Per.C6 Technology To Glaxosmithkline
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics have announced that Crucell has signed a PER.C6 research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6 technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products....
- Research articles 2004-10-01
- Crucell enters licensing agreement with Novavax.(Roundup)(Brief Article)
- Crucell NV and Novavax Inc. have entered into a licensing agreement to offer vaccine manufacturing services for clinical grade materials using Crucell's PER.C6 technology. In addition, Novavax will use Crucell's PER.C6 technology for research on two targeted vaccines. Crucell will receive upfront and annual payments, as...
- Research articles 2003-09-29
- Crucell Annual General Meeting of Shareholders to be Held in Leiden on June 2, 2006
- Leiden, The Netherlands, May 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) has announced that its Annual General Meeting of Shareholders AGM will be held at the Pieterskerk in Leiden on June 2, 2006, commencing...
- Research articles 2006-05-15
- Crucell Announces STAR(TM) Technology Research License Agreement
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has started an evaluation program with Novartis AG. The program will apply Crucell's STARTM technology for the selection of biopharmaceuticals production cell lines...
- Research articles 2006-09-14
- Crucell Announces Completion of Acquisition of SBL Vaccin AB
- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) (Swiss Exchange: CRX) announced today that it has completed the acquisition of SBL Vaccin AB. About Crucell Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) (Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines...
- Research articles 2006-11-23
- Rhein Biotech shareholders approve merger with Crucell subsidiary
- PRESS RELEASE Rhein Biotech shareholders approve merger with Crucell subsidiary Leiden, The Netherlands, December 22, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) has announced that Rhein Biotech N.V. shareholders, voting at...
- Research articles 2006-12-22
- Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial
- Leiden, The Netherlands, April 4, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that the Rabies monoclonal antibody product it is developing has entered a Phase I clinical study in India, four months after launching a similar study in the US. Crucell has...
- Research articles 2007-04-04
- Crucell Appoints Mr. Cees de Jong as Chief Operating Officer
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the appointment of Mr. Cees de Jong to the position of Chief Operating Officer. Mr. de Jong will serve as a member of Crucell's Management Committee. "Cees de Jong is an experienced senior executive and we...
- Research articles 2007-09-10
- Crucell Nominates Cees de Jong as Management Board Member
- Leiden, The Netherlands, 11 February 2008 - Dutch biotechnology company Crucell N.V. today announced the nomination of Dr. Cees de Jong (1961) to join its Management Board. This nomination will be proposed to Crucell's shareholders at...
- Research articles 2008-02-11
- Research and Markets: New and Comprehensive Analysis of Crucell NV Now Available
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c88880) has announced the addition of "Analysis of Crucell NV" to their offering. We present Analysis of Crucell. A complete and comprehensive analysis of Crucell, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and...
- Research articles 2008-04-16
- Wyeth in early-stage negotiations to buy Crucell
- Crucell, a Dutch vaccine and biopharmaceuticals maker, said yesterday that it was in friendly but early-stage talks over a potential takeover by US drugmaker, Wyeth. A deal to buy Crucell, which has a market capitalisation of about €750m ($1bn), would strengthen Wyeth's already formidable franchise in vaccines - a fast-growing...
- News items 2009-08-07
- Crucell grants Merck & Co., Inc. access to vaccine technology
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) announced today that Merck & Co., Inc. (Whitehouse Station, NJ) has exercised an option for the exclusive use of Crucell's PER.C6® technology and an option for access to Crucell's AdVac® vaccine technology in two infectious disease areas.
- Research articles 2007-09-10
- Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a cross-licensing agreement with Merck & Co., Inc. In addition to previously licensed rights to PER.C6, the agreement opens the...
- Research articles 2006-12-27
- Crucell/Merial Sign License Pact For Per.C6 Technology
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and Merial, a world-leading animal health company, have entered into a license agreement for the utilization of Crucell's PER.C6 technology for the development and commercialization of veterinary vaccines for foot-and-mouth disease FMD. FMD is a highly communicable disease of production animals and...
- Research articles 2004-12-01
- Crucell, Kimron sign vaccine pact. (Markets: Life Sciences).
- THE DUTCH vaccine and antibody company Crucell NV and the Kimron Veterinary Institute of Israel, the research arm of the Veterinary Services of the Israeli Ministry of Agriculture, have formed a licensing agreement for developing a veterinary vaccine for the West Niles virus. ...
- Research articles 2003-06-16
- Crucell Files for Cancellation of Remaining Berna Biotech Minority Shares
- Leiden, The Netherlands/Berne, Switzerland, April 12, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) and Berna Biotech AG (Swiss Exchange: BBIN) announced today that Crucell holds more than 98% of all issued...
- Research articles 2006-04-12
- << Previous
- page 1 of 1
- Next >>
